Improving the antimicrobial activity of old antibacterial drug mafenide: Schiff bases and their bioactivity targeting resistant pathogens

Future Med Chem. 2023 Feb;15(3):255-274. doi: 10.4155/fmc-2022-0259. Epub 2023 Mar 9.

Abstract

Background: Increasing rates of acquired resistance have justified the critical need for novel antimicrobial drugs. One viable concept is the modification of known drugs. Methods & results: 21 mafenide-based compounds were prepared via condensation reactions and screened for antimicrobial efficacy, which demonstrated promising activity against both Gram-positive and Gram-negative pathogens, pathogenic fungi and mycobacterial strains (minimum inhibitory concentrations from 3.91 μM). Importantly, they retained activity against a panel of superbugs (methicillin- and vancomycin-resistant staphylococci, enterococci, multidrug-resistant Mycobacterium tuberculosis) without any cross-resistance. Unlike mafenide, most of its imines were bactericidal. Toxicity to HepG2 cells was also investigated. Conclusion: Schiff bases were significantly more active than the parent drug, with iodinated salicylidene and 5-nitrofuran/thiophene-methylidene scaffolds being preferred in identifying the most promising drug candidates.

Keywords: Schiff bases; antibacterial activity; antifungal activity; antimycobacterial activity; cytotoxicity; drug resistance; enterococci; imine; mafenide; staphylococci.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Infective Agents*
  • Mafenide
  • Microbial Sensitivity Tests
  • Mycobacterium tuberculosis*
  • Schiff Bases / pharmacology

Substances

  • Mafenide
  • Schiff Bases
  • Anti-Bacterial Agents
  • Anti-Infective Agents